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Technology now exists for rapid screening of mutated
laboratory mice to identify phenotypes associated with
specific genetic mutations. Large repositories exist for
spontaneous mutants and those induced by chemical
mutagenesis, many of which have never been fully
studied or comprehensively evaluated. To supplement
these resources, a variety of techniques have been
consolidated in an international effort to create muta-
tions in all known protein coding genes in the mouse.
With targeted embryonic stem cell lines now available
for almost all protein coding genes and more recently
CRISPR/Cas9 technology, large-scale efforts are under-
way to create further novel mutant mouse strains and
to characterize their phenotypes. However, accurate
diagnosis of skin, hair, and nail diseases still relies on
careful gross and histological analysis, and while not
automated to the level of the physiological phenotyp-
ing, histopathology still provides the most direct and
accurate diagnosis and correlation with human dis-
eases. As a result of these efforts, many new mouse
dermatological disease models are being characterized
and developed.
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INTRODUCTION
Alopecia areata is a highly complex polygenic disease
(Sundberg et al., 2004; Petukhova et al., 2010). While most
research remains focused on the immunopathogenesis of the
disease, the end result is disruption of hair shaft growth
causing weakness, breakage, and ultimately baldness. Even
though advances are being made, the full repertoire of
proteins and genes involved in pathogenesis of alopecia
areata, as well as those involved in controlling typical hair
follicle and shaft formation and maintenance have yet to be
identified (Sundberg et al., 2014). This raises the question of
how to identify candidate genes and validate them as to their
involvement in alopecia areata or other skin diseases.
Over the last decade, large-scale chemical (N-ethyl-N-
nitrosourea and ethylmethanesulphonate) mutagenesis pro-
jects were started as a phenotype-driven approach to address
the need for mouse models of diseases (Justice et al., 1999).
This provided an additional resource to the valuable
collections of spontaneous mutant mice maintained in
repositories. Many of these induced and spontaneous
mutants have been poorly or incompletely characterized or
are still awaiting characterization, yet the vast majority of
disease-associated mutations in humans are, like these,
missense and nonsense (Kryukov et al., 2007; Cooper et al.,
2013), with splice site mutations and small insertion/deletions
as the next most common. These are often hypomorphic
alleles in which there is partial loss of function or reduced
expression, and represent potentially powerful and very
valuable resources to understand human disease.
THE KNOCKOUT MOUSE PHENOTYPING PROGRAM
The ability to generate point mutations at a predictable
frequency using N-ethyl-N-nitrosourea provoked the develop-
ment of high-throughput, broad coverage approaches to
analyze mutant mouse phenotypes. Such high-throughput
methods include, amongst others, traditional clinical pathol-
ogy (hematology and blood chemistry), behavior, sensory
motor function, and morphological parameters together with
physiological functions such as blood pressure and glucose
tolerance (Brown et al., 2005), which collectively are referred
to as physiological phenotyping (Schofield et al., 2011;
Schofield et al., 2012). While physiological phenotyping
methodologies have been refined and standardized over
time, detailed histopathology (pathological phenotyping) has
been implemented by some centers as part of a primary/
primary extended screen or included as a targeted study on
triaged cases. These mutagenesis projects are now being
augmented by the large-scale generation of genetically
engineered embryonic stem cell lines (Collins et al., 2007)
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that are now being turned into novel mutant mouse strains by
the NIH-supported Knockout Mouse Phenotyping Program for
systematic screening for phenotypes in the International
Mouse Phenotyping Consortium (Brown and Moore, 2012).
These groups are applying a broad array of standardized
phenotyping modalities on a uniform genetic background and
providing that data to the scientific community in real time
(https://www.mousephenotype.org/impress/protocol/102/7).
In addition, there are ongoing massive aging programs
using ‘‘wild type’’ inbred (Yuan et al., 2009; Sundberg et al.,
2011) and genetic reference populations of diversity outcross
(Churchill et al., 2012; Svenson et al., 2012) and Collaborative
Cross mice (Churchill et al., 2004; Chesler et al., 2008).
While these physiological phenotyping approaches provide
high-throughput screening with relatively low costs, many
phenotypes are still missed as the scope of phenotyping is
necessarily limited. Histopathology provides one of the few
ways to accurately diagnose skin, hair, and nail abnormalities
and often provides direct correlation to a human disease. In
fact, the two approaches are complementary; histopathology
will detect phenotypes not detected by physiological screens,
will target additional screens to specific organ systems,
will add value (e.g. structural basis of the phenotype) to
physiological screens, and provides an integrative view based
on whole-animal interpretation of findings.
The objective of many of these studies is a high-throughput
screen that can be followed up by investigators interested in
the diseases discovered in much more detail (secondary
phenotyping). The International Mouse Phenotyping Consor-
tium program uses one inbred strain, the C57BL/6N, a
minimum of two females and two males, for a primary
histological screen, thereby providing a relatively comprehen-
sive overview of major lesions induced by a single gene
mutation. Unfortunately not all groups performing these
studies evaluate the skin and adnexa and those that do have
not used a standard shared protocol. For example, in a pilot
study, the Wellcome Trust Sanger Institute provided one or
two dorsal skin biopsies from 15-week-old females from each
mutated strain to a pathologist for review (DiTommaso et al.,
2014). Studies at The Jackson Laboratory focusing on skin
diseases use two female and two male retired breeders,
neonatal mice (if pups fail to thrive), or preterm embryos (for
strains with embryonic lethality). Skin is collected from seven
sites plus digits to include the nail unit, on retired breeders and
neonatal mice, while the whole embryo is examined in
embryonic lethal phenotypes. Full necropsies are done on
mice with histologic phenotypes of the skin. This follows well
established primary screen phenotyping approaches used for
mutant mice (Sundberg et al., 1998). Wild-type control mice
are included on a regular basis to screen for genetic drift with
time, infectious diseases, or other untoward, unanticipated
events that might affect the final interpretation. Further, cancer
and some degenerative disease lesions are not detectable by
physiological or behavioral assays at 15 weeks of age, the age
when most centers phenotype Knockout Mouse Phenotyping
Program mice. The cost of aging mice up to 18–24 months of
age is prohibitive as a first level screen and hence is not done.
Now that methods have been optimized for creating these
mutants on a large scale, it is possible to evaluate 10–15 new
mutant lines per week using this four mouse approach. One
big surprise has been the relatively low number of lines that
consistently develop lesions as opposed to incidental lesions
found occasionally in isolated individuals. The results so far
suggest several different conclusions: (1) that there are rather
few genes involved in skin and adnexal development and
health that have not already been identified in hypothesis-
driven studies, (2) many genes, and subsequently species,
have evolved genetic paralogs that can partially or fully
recapitulate the functions of the lost gene (i.e. gene/protein
families), and/or (3) genes work in very complex pathways
involving many upstream and downstream partners, which
can, at least partially, account for the loss of one member of
the network. The screening has so far only covered a small
fraction of the genome (496 genes complete at the time of
writing–January 2015, https://www.mousephenotype.org/-,
with 4900 started and 600 from the previous EUMODIC
and other smaller-scale projects). Many strains so far
were nominated because of existing interest. It remains
to be seen whether numerous skin mutants will be iden-
tified by this approach or if more focused mutagenesis
approaches will be needed to create such models. The aim
of this project is to create and phenotype 15,000 true null
mutants by 2021.
THE JACKSON LABORATORY MOUSE MUTANT
RESOURCE
In contrast to the various mutagenesis and knockout mouse
programs existing worldwide, The Jackson Laboratory Mouse
Mutant Resource has been collecting and maintaining mice
with spontaneous mutations since the 1940s (Sundberg et al.,
1995). As a phenotype-driven approach, these strains by
definition display phenotypes of interest. While historically
the bottleneck in developing spontaneous disease models has
been identification of the causative mutations, the advent of
massively parallel sequencing now allows for the near routine
identification of a significant proportion of these mutated
genes relatively cheaply and quickly. Many of the mutants
are hypomorphic alleles, which often more accurately model
spontaneous human diseases compared with null mutant
alleles. Grouping of these mice with similar phenotypes due
to different mutated genes validates molecular pathways or
defines novel ones. Furthermore, systematic histological
evaluation of these mice has often proven to be a relatively
rapid way to correlate these phenotypes with human diseases.
The real added value of these mice as models is not just that
they are being described and compared with specific human
diseases, but that both the mice and data sets developed are
rapidly made publicly available. As these novel models are
published they are made freely available through The Jackson
Laboratory (http://mousemutant.jax.org/). Matching photomi-
crographs of representative images of the mutant phenotypes
are found online (Mouse Genome Informatics Database (http://
informatics.jax.org), Mouse Tumor Biology Database (http://
tumor.informatics.jax.org) for cancer models and the European
Mouse Pathology Database (http://pathbase.net) for general
disease categories. These combined resources can now
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provide a massive resource to study not only skin diseases but
diseases of all organ systems.
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